# Effectiveness of Clopidogrel Resinate in PCI(PRIDE)

Study · id `cardio:ct-nct01349777` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01349777](<https://clinicaltrials.gov/study/NCT01349777>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01349777

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1056 participants.

## Technical summary

Registry record NCT01349777. Randomized; no masking; primary purpose prevention. Start 2010-03-15 (actual); primary completion 2017-03-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1056 participants (enrolled count; ClinicalTrials.gov record NCT01349777, source copy `cardio:ctgov-nct01349777-2017-06-16`, retrieved 2026-10-26)
- Started: 2010-03-15 (actual) (ClinicalTrials.gov record NCT01349777, source copy `cardio:ctgov-nct01349777-2017-06-16`, retrieved 2026-10-26)
- Primary completion: 2017-03-14 (actual) (ClinicalTrials.gov record NCT01349777, source copy `cardio:ctgov-nct01349777-2017-06-16`, retrieved 2026-10-26)
- Completion: 2017-03-14 (actual) (ClinicalTrials.gov record NCT01349777, source copy `cardio:ctgov-nct01349777-2017-06-16`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01349777, source copy `cardio:ctgov-nct01349777-2017-06-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01349777-2017-06-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness of Clopidogrel Resinate in PCI(PRIDE)
- Condition: Coronary Artery Disease
- Intervention (Drug): Pregrel®
- Intervention (Drug): Plavix®
- Lead sponsor: Seung-Jung Park
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Seung-Jung Park (`cardio:org-seung-jung-park`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)

## Provenance

Content hash: da87488f964568d29b4f9963cbcd3a3b547c8e69d057db64b93b47d98661d773
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
